FDA 483 - Takeda GmbH, Plant Oranienburg - March 16, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Takeda GmbH, Plant Oranienburg, identified significant deficiencies in the firm's investigation processes. The company failed to thoroughly investigate unexplained discrepancies, including metal contamination in drug product batches, and did not determine root causes or implement corrective actions. Additionally, customer complaint investigations for broken tablets were not expanded to include other relevant batches, leading to the commercial release of potentially affected products.
ID · b1d4c194-35ae-4a76-be53-87964288a843